FindTrial
Sign In

Prospective multicenter clinical trial for MRI/CT guided brachytherapy with combined three-dimensional intracavitary/interstitial brachytherapy techniques versus intracavitary brachytherapy combined with external irradiation supplement for locally advanced cervical cancer

Prospective multicenter clinical trial for MRI/CT guided brachytherapy with combined three-dimensional intracavitary/interstitial brachytherapy techniques versus intracavitary brachytherapy combined with external irradiation supplement for locally advanced cervical cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1800018996
Enrollment
Unknown
Registered
2018-10-20
Start date
2018-11-01
Completion date
Unknown
Last updated
2018-10-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cervical cancer

Interventions

Group A:MRI/CT guided brachytherapy with combined three-dimensional intracavitary/interstitial brachytherapy techniques
Group B:intracavitary brachytherapy combined with external irradiation supplement

Sponsors

China-Japan Union Hospital of Jilin University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 75 years old; 2. KPS=60; 3. Pathologically confirmed cervical cancer; 4. FIGO staging locally advanced cervical cancer (1B2/2A2/2B and above); 5. Received the radical radiotherapy; 6. The brachytherapy combined with external radiotherapy; 7. The external radiotherapy including the three-dimensional conformal external beam radiotherapy or IMRT technology; 8. The brachytherapy including MRI/CT guided brachytherapy with combined three-dimensional intracavitary/interstitial brachytherapy techniques or intracavitary brachytherapy combined with external irradiation supplement.

Exclusion criteria

Exclusion criteria: 1. Previous or concomitant other cancers; 2. Other serious illnesses; 3. Failure to follow-up after treatment; 4. The data is missing or incomplete.

Design outcomes

Primary

MeasureTime frame
Local control rate;Cancer recurrence rate;Normal tissue side effects;Overall Survival;Progression-Free Survival;Quality of life;—

Countries

China

Contacts

Public ContactCheng Guanghui

China-Japan Union Hospital of Jilin University

wuning@jlu.edu.cn+86 13504334509

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026